Citrulline supplementation restores T-cell function and immunotherapy efficacy. A–C, Serum and TIF were isolated from mice consuming sucralose-supplemented (0.09 mg/mL) drinking water or regular drinking water for 14 days prior to tumor injection and throughout tumor growth. High-resolution LC-HRMS metabolomic analysis was performed. A, Pathway analysis of TIF, with significant pathways shown. B, Volcano plot comparing metabolite abundance from the TIF of mice consuming sucralose in the drinking water vs. regular water. C, Quantification of arginine abundance within the serum and TIF of mice indicated. D, Taconic mice were given sucralose-supplemented (0.09 mg/mL) or control drinking water in the presence of absence of arginine or citrulline (3.75 mg/mL) for 2 weeks prior to tumor injection and throughout the duration of the experiment. Mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with 200 µg anti–PD-1 at days 9, 12, and 15. E, Quantification of IFNγ+ CD8+ T cells and CD4+ Tconv cells within the tumor 14 days after tumor injection. F and G, Tumor growth curves of mice from experiment described in D. G, Tumor growth curves from experiment described in D. Data are a composite of three (E–H), two (C), or one (A and B) independent experiments with 3–5 mice per group per experiment. Error bars represent the mean ± SEM. The Student t test (C), one-way ANOVA with the Tukey multiple comparisons test (E), two-way ANOVA (F and G), and Mantel–Cox (H) were used. *, P < 0.05; **, P < 0.005; ****, P < 0.00005.